33 research outputs found
Scaling up the delivery of refractive error services within a district health system: the KwaZulu-Natal, South Africa experience
Contrasting Inflammatory Signatures in Peripheral Blood and Bronchoalveolar Cells Reveal Compartment-Specific Effects of HIV Infection
The mechanisms by which HIV increases susceptibility to tuberculosis and other
respiratory infections are incompletely understood. We used transcriptomics of paired
whole bronchoalveolar lavage cells (BLCs) and peripheral blood mononuclear cells to
compare the effect of HIV at the lung mucosal surface and in peripheral blood. The
majority of HIV-induced differentially expressed genes (DEGs) were specific to either the
peripheral or lung mucosa compartments (1,307/1,404, 93%). Type I interferon signaling
was the dominant signature of DEGs in HIV-positive blood but not in HIV-positive BLCs.
DEGs in the HIV-positive BLCs were significantly enriched for infiltration with cytotoxic
CD8+ T cells. Higher expression of type 1 interferon transcripts in peripheral CD8+ T
cells and representative transcripts and proteins in BLCs-derived CD8+ T cells during HIV
infection, including IFNG (IFN-gamma), GZMB (Granzyme B), and PDCD1 (PD-1), was
confirmed by cell-subset specific transcriptional analysis and flow cytometry. Thus, we
report that a whole transcriptomic approach revealed qualitatively distinct effects of HIV in
blood and bronchoalveolar compartments. Further work exploring the impact of distinct
type I interferon programs and functional features of CD8+ T cells infiltrating the lung
mucosa during HIV infection may provide novel insights into HIV-induced susceptibility
to respiratory pathogens
HPLC-based purification and isolation of potent anti-HIV and latency reversing Daphnane Diterpenes from the medicinal plant Gnidia sericocephala (Thymelaeaceae)
Despite the success of combination antiretroviral therapy (cART), HIV persists in low- and
middle-income countries (LMIC) due to emerging drug resistance and insufficient drug accessibility.
Furthermore, cART does not target latently-infected CD4+ T cells, which represent a major barrier to
HIV eradication. The “shock and kill” therapeutic approach aims to reactivate provirus expression in
latently-infected cells in the presence of cART and target virus-expressing cells for elimination. An
attractive therapeutic prototype in LMICs would therefore be capable of simultaneously inhibiting
viral replication and inducing latency reversal. Here we report that Gnidia sericocephala, which is
used by traditional health practitioners in South Africa for HIV/AIDS management to supplement
cART, contains at least four daphnane-type compounds (yuanhuacine A (1), yuanhuacine as part
of a mixture (2), yuanhuajine (3), and gniditrin (4)) that inhibit viral replication and/or reverse HIV
latency. For example, 1 and 2 inhibit HIV replication in peripheral blood mononuclear cells (PBMC)
by >80% at 0.08 g/mL, while 1 further inhibits a subtype C virus in PBMC with a half-maximal
effective concentration (EC50) of 0.03 M without cytotoxicity. Both 1 and 2 also reverse HIV latency
in vitro consistent with protein kinase C activation but at 16.7-fold lower concentrations than the
control prostratin. Both 1 and 2 also reverse latency in primary CD4+ T cells from cART-suppressed
donors with HIV similar to prostratin but at 6.7-fold lower concentrations. These results highlight G.
sericocephala and components 1 and 2 as anti-HIV agents for improving cART efficacy and supporting
HIV cure efforts in resource-limited regions.SUPPLEMENTARY MATERIAL : TABLE S1: Anti-HIV replication activity of the positive control efavirenz using the in vitro deCIPhR assay: TABLE S2: Anti-HIV replication activity of G. sericocephala root extracts using the in vitro deCIPhR assay: TABLE S3: Cytotoxicity of G. sericocephala root extracts using the in vitro deCIPhR assay; FIGURE S1: 1H NMR data of yuanhuacine A (1), acquired on a Bruker Avance III HD 500 MHz NMR spectrophotometer with Prodigy Probe, the compound dissolved in deuterated chloroform (CDCl3): FIGURE S2: 13C NMR data of yuanhuacine A (1), acquired on a Bruker Avance III HD 500 MHz NMR spectrophotometer with Prodigy Probe, the compound dissolved in deuterated chloroform (CDCl3): FIGURE S3: The DEBT NMR data of yuanhuacine A (1), acquired on a Bruker Avance III HD 500 MHz NMR spectrophotometer with Prodigy Probe, the compound dissolved in deuterated chloroform (CDCl3).Funding was provided by the South African Department of Science and Innovation
(DST/CON 0031/2019), Canadian Institutes for Health Research (CIHR PJT-153057) (I.T.) and the New
Frontiers in Research Fund—Explorations (NFRFE-2018-01386) (I.T.). This work was also supported
through the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE) (I.T.; N.G.),
a DELTAs African Initiative [grant # DEL-15-006]. The DELTA African Initiative is an independent
funding scheme of the African Academy of Sciences (AAS)’s Alliance for Accelerating Excellence
in Science in Africa (AESA) and supported by the New Partnership for Africa’s Development
Planning and Coordinating Agency (NEPAD Agency) with funding from the Welcome Trust [grant #
107752/Z/15/Z] and the UK government. This work was also supported by grants to L.J.M.: Beyond
Antiretroviral Treatment (BEAT)-HIV Delaney Collaboratory Grants UM1AI126620 and UM1AI64570.
It was also supported by the Robert I. Jacobs Fund of the Philadelphia Foundation; Penn Center for
AIDS Research Grant P30 AI 045880; and the Herbert Kean. The APC was funded by University of
Pretoria and Deaprtment of Science and Innovation.https://www.mdpi.com/journal/virusesam2023Chemistr
Global patient outcomes after elective surgery: prospective cohort study in 27 low-, middle- and high-income countries.
BACKGROUND: As global initiatives increase patient access to surgical treatments, there remains a need to understand the adverse effects of surgery and define appropriate levels of perioperative care. METHODS: We designed a prospective international 7-day cohort study of outcomes following elective adult inpatient surgery in 27 countries. The primary outcome was in-hospital complications. Secondary outcomes were death following a complication (failure to rescue) and death in hospital. Process measures were admission to critical care immediately after surgery or to treat a complication and duration of hospital stay. A single definition of critical care was used for all countries. RESULTS: A total of 474 hospitals in 19 high-, 7 middle- and 1 low-income country were included in the primary analysis. Data included 44 814 patients with a median hospital stay of 4 (range 2-7) days. A total of 7508 patients (16.8%) developed one or more postoperative complication and 207 died (0.5%). The overall mortality among patients who developed complications was 2.8%. Mortality following complications ranged from 2.4% for pulmonary embolism to 43.9% for cardiac arrest. A total of 4360 (9.7%) patients were admitted to a critical care unit as routine immediately after surgery, of whom 2198 (50.4%) developed a complication, with 105 (2.4%) deaths. A total of 1233 patients (16.4%) were admitted to a critical care unit to treat complications, with 119 (9.7%) deaths. Despite lower baseline risk, outcomes were similar in low- and middle-income compared with high-income countries. CONCLUSIONS: Poor patient outcomes are common after inpatient surgery. Global initiatives to increase access to surgical treatments should also address the need for safe perioperative care. STUDY REGISTRATION: ISRCTN5181700
The evolving SARS-CoV-2 epidemic in Africa: insights from rapidly expanding genomic surveillance
Investment in SARS-CoV-2 sequencing in Africa over the past year has led to a major increase in the number of sequences generated, now exceeding 100,000 genomes, used to track the pandemic on the continent. Our results show an increase in the number of African countries able to sequence domestically, and highlight that local sequencing enables faster turnaround time and more regular routine surveillance. Despite limitations of low testing proportions, findings from this genomic surveillance study underscore the heterogeneous nature of the pandemic and shed light on the distinct dispersal dynamics of Variants of Concern, particularly Alpha, Beta, Delta, and Omicron, on the continent. Sustained investment for diagnostics and genomic surveillance in Africa is needed as the virus continues to evolve, while the continent faces many emerging and re-emerging infectious disease threats. These investments are crucial for pandemic preparedness and response and will serve the health of the continent well into the 21st century
South African Paediatric Surgical Outcomes Study : a 14-day prospective, observational cohort study of paediatric surgical patients
BACKGROUND : Children comprise a large proportion of the population in sub-Saharan Africa. The burden of paediatric surgical disease exceeds available resources in Africa, potentially increasing morbidity and mortality. There are few prospective paediatric perioperative outcomes studies, especially in low- and middle-income countries (LMICs).
METHODS : We conducted a 14-day multicentre, prospective, observational cohort study of paediatric patients (aged <16 yrs) undergoing surgery in 43 government-funded hospitals in South Africa. The primary outcome was the incidence of in-hospital postoperative complications.
RESULTS : We recruited 2024 patients at 43 hospitals. The overall incidence of postoperative complications was 9.7% [95% confidence interval (CI): 8.4–11.0]. The most common postoperative complications were infective (7.3%; 95% CI: 6.2–8.4%). In-hospital mortality rate was 1.1% (95% CI: 0.6–1.5), of which nine of the deaths (41%) were in ASA physical status 1 and 2 patients. The preoperative risk factors independently associated with postoperative complications were ASA physcial status, urgency of surgery, severity of surgery, and an infective indication for surgery.
CONCLUSIONS : The risk factors, frequency, and type of complications after paediatric surgery differ between LMICs and high-income countries. The in-hospital mortality is 10 times greater than in high-income countries. These findings should be used to develop strategies to improve paediatric surgical outcomes in LMICs, and support the need for larger prospective, observational paediatric surgical outcomes research in LMICs.
CLINICAL TRIAL REGISTRATION : NCT03367832.Jan Pretorius Research Fund; Discipline of Anaesthesiology and Critical Care, Nelson R Mandela School of Medicine, University of KwaZulu-Natal; Department of Anaesthesia and Perioperative Medicine, Groote Schuur Hospital and University of Cape Town; Department of Anaesthesia, University of the Witwatersrand; and the Paediatric Anaesthesia Community of South Africa (PACSA).https://bjanaesthesia.org2020-02-01gl2019Anaesthesiolog
The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance.
Investment in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequencing in Africa over the past year has led to a major increase in the number of sequences that have been generated and used to track the pandemic on the continent, a number that now exceeds 100,000 genomes. Our results show an increase in the number of African countries that are able to sequence domestically and highlight that local sequencing enables faster turnaround times and more-regular routine surveillance. Despite limitations of low testing proportions, findings from this genomic surveillance study underscore the heterogeneous nature of the pandemic and illuminate the distinct dispersal dynamics of variants of concern-particularly Alpha, Beta, Delta, and Omicron-on the continent. Sustained investment for diagnostics and genomic surveillance in Africa is needed as the virus continues to evolve while the continent faces many emerging and reemerging infectious disease threats. These investments are crucial for pandemic preparedness and response and will serve the health of the continent well into the 21st century
The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance
INTRODUCTION
Investment in Africa over the past year with regard to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequencing has led to a massive increase in the number of sequences, which, to date, exceeds 100,000 sequences generated to track the pandemic on the continent. These sequences have profoundly affected how public health officials in Africa have navigated the COVID-19 pandemic.
RATIONALE
We demonstrate how the first 100,000 SARS-CoV-2 sequences from Africa have helped monitor the epidemic on the continent, how genomic surveillance expanded over the course of the pandemic, and how we adapted our sequencing methods to deal with an evolving virus. Finally, we also examine how viral lineages have spread across the continent in a phylogeographic framework to gain insights into the underlying temporal and spatial transmission dynamics for several variants of concern (VOCs).
RESULTS
Our results indicate that the number of countries in Africa that can sequence the virus within their own borders is growing and that this is coupled with a shorter turnaround time from the time of sampling to sequence submission. Ongoing evolution necessitated the continual updating of primer sets, and, as a result, eight primer sets were designed in tandem with viral evolution and used to ensure effective sequencing of the virus. The pandemic unfolded through multiple waves of infection that were each driven by distinct genetic lineages, with B.1-like ancestral strains associated with the first pandemic wave of infections in 2020. Successive waves on the continent were fueled by different VOCs, with Alpha and Beta cocirculating in distinct spatial patterns during the second wave and Delta and Omicron affecting the whole continent during the third and fourth waves, respectively. Phylogeographic reconstruction points toward distinct differences in viral importation and exportation patterns associated with the Alpha, Beta, Delta, and Omicron variants and subvariants, when considering both Africa versus the rest of the world and viral dissemination within the continent. Our epidemiological and phylogenetic inferences therefore underscore the heterogeneous nature of the pandemic on the continent and highlight key insights and challenges, for instance, recognizing the limitations of low testing proportions. We also highlight the early warning capacity that genomic surveillance in Africa has had for the rest of the world with the detection of new lineages and variants, the most recent being the characterization of various Omicron subvariants.
CONCLUSION
Sustained investment for diagnostics and genomic surveillance in Africa is needed as the virus continues to evolve. This is important not only to help combat SARS-CoV-2 on the continent but also because it can be used as a platform to help address the many emerging and reemerging infectious disease threats in Africa. In particular, capacity building for local sequencing within countries or within the continent should be prioritized because this is generally associated with shorter turnaround times, providing the most benefit to local public health authorities tasked with pandemic response and mitigation and allowing for the fastest reaction to localized outbreaks. These investments are crucial for pandemic preparedness and response and will serve the health of the continent well into the 21st century
Are scientists barking up the wrong tree to “scientifically validate” traditional medicines?
In South Africa it is estimated that at least 70% of South Africans consult one of the more than 200,000 Traditional Healers in the country. Clearly traditional health practitioners in South Africa play a crucial role in providing primary health care to the majority of the population. This knowledge system together with South Africa's unique biodiversity provides valuable resources for scientists to undertake research in search of new pharmaceuticals, nutraceuticals and cosmeceuticals. Scientists often refer to this as “scientific validation of traditional medicines” which can be misleading to holders of the traditional knowledge since traditional health practitioners treat their patients holistically using traditional medicines consisting of one or more plant species. Four case studies i.e. appetite suppressant form Hoodia gordonii, monatin from Sclerochiton ilicifolius, mosquito repellent from Lippia javanica and the treatment of benign prostate hyperplasia (BPH) and male pattern baldness from Elephantorrhiza elephantina which were either commercialized or close to commercialization are described and in all cases these have followed the classical drug discovery or product development route. These case studies have led to the realization that the traditional use of the plants were not exactly the same as the commercialized use. Often the scientists select plants based on traditional use and through scientific intervention discover similar biological activities or different biological activities of the plant species or constituents thereof. The scientific discoveries are further developed and the route to commercialization requires huge investment, time and resources. Hence it could be concluded that the approach has not been to scientifically validate the traditional uses of plants or traditional medicines. As scientists we need to be responsible when utilizing traditional knowledge in our research approaches and it is important to share benefits with the owners of indigenous knowledge.The CSIRhttp://www.elsevier.com/locate/sajb2020-11-01hj2019Chemistr